Royalty Pharma plc (RPRX)

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Headquarters: New York, NY, US · Employees: 100 · Website: https://www.royaltypharma.com

Supply-chain relationships for RPRX

• EXELIXIS, INC. (EXEL) — partner

Frequently asked questions about Royalty Pharma plc (RPRX)

What is Royalty Pharma plc (RPRX)?

Royalty Pharma plc (RPRX) is a publicly traded company in the Pharmaceutical Preparations sector (Biotechnology), listed on Nasdaq. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.

Who are Royalty Pharma plc's key suppliers and customers?

Macroplane tracks Royalty Pharma plc's (RPRX) supply chain. Tracked supply-chain partners include EXELIXIS, INC. (EXEL).